Pharmacotherapies for diabetic retinopathy: Present and future

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.

Original languageEnglish
Article number52487
JournalExperimental Diabesity Research
Volume2007
DOIs
StatePublished - Aug 21 2007
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Blindness
ruboxistaurin
Fluocinolone Acetonide
Drug Therapy
Triamcinolone Acetonide
Hyaluronoglucosaminidase
Temazepam
Macular Edema
Light Coagulation
Vitrectomy
Dexamethasone
Vascular Endothelial Growth Factor A
Blood Glucose
Lasers
Blood Pressure
Lipids
Equipment and Supplies
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacotherapies for diabetic retinopathy : Present and future. / Schwartz, Stephen; Flynn, Harry W.

In: Experimental Diabesity Research, Vol. 2007, 52487, 21.08.2007.

Research output: Contribution to journalArticle

@article{ddaa827f65fd44c9ac2508dd5f977bb1,
title = "Pharmacotherapies for diabetic retinopathy: Present and future",
abstract = "Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.",
author = "Stephen Schwartz and Flynn, {Harry W}",
year = "2007",
month = "8",
day = "21",
doi = "10.1155/2007/52487",
language = "English",
volume = "2007",
journal = "Experimental Diabetes Research",
issn = "1687-5214",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Pharmacotherapies for diabetic retinopathy

T2 - Present and future

AU - Schwartz, Stephen

AU - Flynn, Harry W

PY - 2007/8/21

Y1 - 2007/8/21

N2 - Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.

AB - Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.

UR - http://www.scopus.com/inward/record.url?scp=34547869213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547869213&partnerID=8YFLogxK

U2 - 10.1155/2007/52487

DO - 10.1155/2007/52487

M3 - Article

C2 - 17713597

AN - SCOPUS:34547869213

VL - 2007

JO - Experimental Diabetes Research

JF - Experimental Diabetes Research

SN - 1687-5214

M1 - 52487

ER -